A T Cohen

Summary

Affiliation: King's College London
Country: UK

Publications

  1. ncbi request reprint Applying risk assessment models in orthopaedic surgery: effective risk stratification
    A T Cohen
    Department of Medicine, King s College Hospital, London, UK
    Blood Coagul Fibrinolysis 10:S63-70. 1999
  2. ncbi request reprint The significance of distal vein thrombosis and bilateral disease
    A T Cohen
    Department of Surgery, Guy s, King s and St Thomas School of Medicine, Bessemer Road, London, UK
    J Thromb Haemost 3:1360-1. 2005
  3. ncbi request reprint Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study
    Raza Alikhan
    Academic Department of Surgery, Guy s, King s, St Thomas School of Medicine, London, UK
    Blood Coagul Fibrinolysis 14:341-6. 2003
  4. ncbi request reprint Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients
    Alexander T Cohen
    Vascular Medicine, Department of Surgery, Guy s, King s and St Thomas School of Medicine, London, UK
    Thromb Haemost 94:750-9. 2005
  5. ncbi request reprint Are placebo-controlled trials ethical in areas where current guidelines recommend therapy? Yes
    A T Cohen
    Vascular Medicine Group, Vascular Department, King s College Hospital, London, UK
    J Thromb Haemost 4:2130-2. 2006
  6. ncbi request reprint Phase III Trials of New Oral Anticoagulants in the Acute Treatment and Secondary Prevention of VTE: Comparison and Critique of Study Methodology and Results
    Alexander T Cohen
    Department of Thrombosis and Haemostasis, Guy s and St Thomas NHS Foundation Trust, London, SE1, UK
    Adv Ther 31:473-93. 2014
  7. doi request reprint The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study
    Alexander T Cohen
    Department of Haematological Medicine, King s College Hospital, London, United Kingdom Electronic address
    Am Heart J 167:335-41. 2014
  8. ncbi request reprint Managing pulmonary embolism from presentation to extended treatment
    Alexander T Cohen
    Department of Haematological Medicine, King s College Hospital, London, UK Electronic address
    Thromb Res 133:139-48. 2014
  9. doi request reprint NOACs for thromboprophylaxis in medical patients
    Alexander Ander T Cohen
    Vascular Medicine, Department of Surgery, King s College Hospital, London, UK
    Best Pract Res Clin Haematol 26:183-90. 2013
  10. doi request reprint Rivaroxaban for thromboprophylaxis in acutely ill medical patients
    Alexander T Cohen
    Department of Vascular Surgery, King s College Hospital, London SE5 9RS, United Kingdom
    N Engl J Med 368:513-23. 2013

Detail Information

Publications47

  1. ncbi request reprint Applying risk assessment models in orthopaedic surgery: effective risk stratification
    A T Cohen
    Department of Medicine, King s College Hospital, London, UK
    Blood Coagul Fibrinolysis 10:S63-70. 1999
    ..Screening for clotting disorders and other additional risk factors may assist identification of very-high-risk patients and allow appropriate targeting of intensive prophylactic therapy...
  2. ncbi request reprint The significance of distal vein thrombosis and bilateral disease
    A T Cohen
    Department of Surgery, Guy s, King s and St Thomas School of Medicine, Bessemer Road, London, UK
    J Thromb Haemost 3:1360-1. 2005
  3. ncbi request reprint Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study
    Raza Alikhan
    Academic Department of Surgery, Guy s, King s, St Thomas School of Medicine, London, UK
    Blood Coagul Fibrinolysis 14:341-6. 2003
    ..22 (95% CI, 0.09-0.51); immobility, 0.53 (95% CI, 0.14-1.72); previous VTE, 0.49 (95% CI, 0.15-1.68); and cancer, 0.50 (95%o CI, 0.14-1.72). The beneficial effects of enoxaparin extend to a wide range of acutely ill medical patients...
  4. ncbi request reprint Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients
    Alexander T Cohen
    Vascular Medicine, Department of Surgery, Guy s, King s and St Thomas School of Medicine, London, UK
    Thromb Haemost 94:750-9. 2005
    ..These medical conditions and risk factors are included in a risk-assessment model which is hoped will provide a simple means of assisting clinicians in deciding whether thromboprophylaxis should be used in an individual patient...
  5. ncbi request reprint Are placebo-controlled trials ethical in areas where current guidelines recommend therapy? Yes
    A T Cohen
    Vascular Medicine Group, Vascular Department, King s College Hospital, London, UK
    J Thromb Haemost 4:2130-2. 2006
  6. ncbi request reprint Phase III Trials of New Oral Anticoagulants in the Acute Treatment and Secondary Prevention of VTE: Comparison and Critique of Study Methodology and Results
    Alexander T Cohen
    Department of Thrombosis and Haemostasis, Guy s and St Thomas NHS Foundation Trust, London, SE1, UK
    Adv Ther 31:473-93. 2014
    ..This review compares and contrasts the design and results of the Phase III trials of NOACs in VTE and discusses the implications of the NOACs in terms of treatment strategies in VTE patients. ..
  7. doi request reprint The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study
    Alexander T Cohen
    Department of Haematological Medicine, King s College Hospital, London, United Kingdom Electronic address
    Am Heart J 167:335-41. 2014
    ....
  8. ncbi request reprint Managing pulmonary embolism from presentation to extended treatment
    Alexander T Cohen
    Department of Haematological Medicine, King s College Hospital, London, UK Electronic address
    Thromb Res 133:139-48. 2014
    ....
  9. doi request reprint NOACs for thromboprophylaxis in medical patients
    Alexander Ander T Cohen
    Vascular Medicine, Department of Surgery, King s College Hospital, London, UK
    Best Pract Res Clin Haematol 26:183-90. 2013
    ..This article briefly summarises our understanding of the background to preventing venous thromboembolism in hospitalised medical patients and reviews the details of the studies using NOACs. ..
  10. doi request reprint Rivaroxaban for thromboprophylaxis in acutely ill medical patients
    Alexander T Cohen
    Department of Vascular Surgery, King s College Hospital, London SE5 9RS, United Kingdom
    N Engl J Med 368:513-23. 2013
    ....
  11. doi request reprint Managing venous thromboembolism in Asia: winds of change in the era of new oral anticoagulants
    Alexander Cohen
    Vascular Medicine, King s College Hospital, London, United Kingdom
    Thromb Res 130:291-301. 2012
    ..Meanwhile, physicians should remain vigilant and strive to act early, decisively and appropriately to diagnose and treat VTE, particularly in patients at high risk...
  12. doi request reprint Long-term benefits of preventing venous thromboembolic events
    Alexander T Cohen
    Surgery and Vascular Medicine, King s College Hospital, London, UK
    Curr Med Res Opin 28:877-89. 2012
    ..Newer oral anticoagulants such as rivaroxaban, dabigatran etexilate, apixaban and edoxaban, which do not have the limitations of established anticoagulants, have been developed...
  13. doi request reprint Thromboprophylaxis in non-surgical cancer patients
    Alexander T Cohen
    Vascular Medicine, Department of Vascular Surgery, King s College Hospital, London, UK
    Thromb Res 129:S137-45. 2012
    ..For ambulatory cancer patients undergoing chemotherapy we recommend LMWH or semuloparin. These are safe and effective agents in the thromboprophylaxis of non-surgical cancer patients...
  14. doi request reprint The use of rivaroxaban for short- and long-term treatment of venous thromboembolism
    Alexander T Cohen
    King s College Hospital, Denmark Hill, London SE5 9RS, UK
    Thromb Haemost 107:1035-43. 2012
    ..Moreover, the simple, once-daily oral administration of rivaroxaban could potentially improve adherence to extended-duration VTE treatment compared with the current standard of care in individuals with confirmed DVT or PE...
  15. pmc Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial
    Alexander T Cohen
    Department of Surgery, Guy s, King s, and St Thomas s School of Medicine, London SE5 9PJ
    BMJ 332:325-9. 2006
    ..To determine the efficacy and safety of the anticoagulant fondaparinux in older acute medical inpatients at moderate to high risk of venous thromboembolism...
  16. ncbi request reprint The use of graduated compression stockings in association with fondaparinux in surgery of the hip. A multicentre, multinational, randomised, open-label, parallel-group comparative study
    A T Cohen
    Department of Vascular Surgery, King s College Hospital, Bessemer Road, London SE5 9RS, UK
    J Bone Joint Surg Br 89:887-92. 2007
    ..88, 95% confidence interval 0.46 to 1.65, p = 0.69). Major bleeding occurred in only one patient. The addition of graduated compression stockings to fondaparinux appears to offer no additional benefit over the use of fondaparinux alone...
  17. ncbi request reprint Thromboprophylaxis with dalteparin in medical patients: which patients benefit?
    Alexander T Cohen
    Department of Surgery, King s College Hospital, Bessemer Road, London SE5 9PJ, UK
    Vasc Med 12:123-7. 2007
    ..Our findings, therefore, support the broad application of thromboprophylaxis in acutely ill hospitalized medical patients...
  18. ncbi request reprint Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality
    Alexander T Cohen
    Vascular Medicine, Department of Surgery, King s College Hospital, London, SE5 9RS, UK
    Thromb Haemost 98:756-64. 2007
    ..Given the availability of effective VTE prophylaxis, many of these events and deaths could have been prevented. These results have important implications for the allocation of healthcare resources...
  19. doi request reprint Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study
    Alexander T Cohen
    King s College Hospital, London, UK
    Lancet 371:387-94. 2008
    ....
  20. ncbi request reprint Will a once-weekly anticoagulant for the treatment and secondary prevention of thromboembolism improve adherence?
    Alexander T Cohen
    Honorary Consultant Vascular Physician, Vascular Medicine, King s College Hospital, London SE5 9RS, UK
    Thromb Haemost 101:422-7. 2009
    ..The advent of novel anticoagulants such as idraparinux with its long half-life offers hope for improved adherence with anticoagulation, and ultimately improved outcomes...
  21. doi request reprint VTE prophylaxis for the medical patient: where do we stand? - a focus on cancer patients
    Alexander T Cohen
    Vascular Medicine, Department of Vascular Surgery, King s College Hospital, London, UK
    Thromb Res 125:S21-9. 2010
    ..There is no evidence for the use of aspirin, warfarin or mechanical methods. We recommend either low molecular weight heparin or fondaparinux as safe and effective agents in the thromboprophylaxis of medical patients...
  22. doi request reprint Asia-Pacific Thrombosis Advisory Board consensus paper on prevention of venous thromboembolism after major orthopaedic surgery
    Alexander T Cohen
    King s College Hospital, London SE5 9RS, UK
    Thromb Haemost 104:919-30. 2010
    ..In conclusion, we call for recognition that VTE is an issue in Asian patients, and that effective thromboprophylaxis is the most important strategy...
  23. pmc Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol
    Alexander Thomas Cohen
    Department of Surgery and Vascular Medicine, King s College Hospital, London SE59RS, UK
    J Thromb Thrombolysis 31:407-16. 2011
    ....
  24. ncbi request reprint Discoveries in thrombosis care for medical patients
    Alexander T Cohen
    Guy s, King s, St Thomas Academic Department of Surgery, London, United Kingdom
    Semin Thromb Hemost 28:13-7. 2002
    ..Low-molecular-weight heparin offers a safe and cost-effective alternative to unfractionated heparin in medical patients; to date, enoxaparin is the only low-molecular-weight heparin licensed for thromboprophylaxis in this indication...
  25. ncbi request reprint Prophylaxis of venous thromboembolism in medical patients
    A T Cohen
    Academic Department of Surgery, Guy s, King s and St Thomas School of Medicine, Bessemer Road, London, SE5 9PJ, UK
    Curr Opin Pulm Med 7:332-7. 2001
    ..As the evidence accumulates and guidelines are strengthened physicians will be able to tailor the use of thromboprophylaxis to the individual patient's needs...
  26. ncbi request reprint Thromboprophylaxis in major abdominal surgery for cancer
    J J Negus
    Vascular Diseases Research Group, Guy s, King s and St Thomas School of Medicine, London SE5 9PJ, UK
    Eur J Surg Oncol 32:911-6. 2006
    ..To review the epidemiology and pathogenesis of venous thromboembolism (VTE) in surgical cancer patients, in addition to the use of thromboprophylaxis in major abdominal surgery, such as low-molecular-weight heparin (LMWH) and fondaparinux...
  27. ncbi request reprint Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study
    Raza Alikhan
    Academic Department of Surgery, Guy s, King s, and St Thomas School of Medicine, London, England
    Arch Intern Med 164:963-8. 2004
    ..There is limited information about risk factors for venous thromboembolism (VTE) in acutely ill hospitalized general medical patients...
  28. ncbi request reprint Meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery
    A T Cohen
    Department of Surgery, Guy s, King s and St Thomas Hospital School of Medicine, London, UK
    Br J Surg 92:1335-44. 2005
    ..Use of low molecular weight heparin (LMWH) is standard practice for preventing postoperative venous thromboembolism (VTE). Ximelagatran is a new direct thrombin inhibitor for this indication...
  29. ncbi request reprint Pharmacological prevention of venous thromboembolism in medical patients at risk
    Mia Wolozinsky
    Academic Department of Surgery, King s College Hospital, London, UK
    Am J Cardiovasc Drugs 5:409-15. 2005
    ..We recommend either LMWH or fondaparinux sodium as well tolerated and effective thromboprophylactic agents in medical patients...
  30. ncbi request reprint Benefits of deep-vein thrombosis prophylaxis in the nonsurgical patient: The MEDENOX trial
    A T Cohen
    Academic Department of Surgery, Guy's, King's and St Thomas' School of Medicine, London, England, UK
    Semin Hematol 38:31-8. 2001
    ..Further studies are required to assess the benefit:risk ratio of therapy in other clearly-defined medical groups...
  31. ncbi request reprint Assessment of bleeding after concomitant administration of antiplatelet and anticoagulant agents in lower limb arthroplasty
    Ola E Dahl
    International Surgical Thrombosis Forum, Thrombosis Research Institute, London, UK
    Pathophysiol Haemost Thromb 35:428-34. 2006
    ..4-12 h) when compared with preoperative (12 h) administration of enoxaparin. Transfusion rates were significantly lower with administration of melagatran/ximelagatran compared with enoxaparin...
  32. doi request reprint An adaptive-design dose-ranging study of PD 0348292, an oral factor Xa inhibitor, for thromboprophylaxis after total knee replacement surgery
    A T Cohen
    Vascular Medicine, Department of Vascular Surgery, King s College Hospital, London, UK
    J Thromb Haemost 11:1503-10. 2013
    ..PD 0348292 is an oral, selective, direct and reversible factor Xa inhibitor. This was an adaptive dose-ranging study evaluating a 100-fold PD 0348292 dose range in subjects undergoing total knee replacement (TKR)...
  33. ncbi request reprint Long-haul flights and deep vein thrombosis: a significant risk only when additional factors are also present
    Roopen Arya
    Department of Haematological Medicine, King s College Hospital, London, UK
    Br J Haematol 116:653-4. 2002
    ..3 (CI 0.6-2.8). Risk of DVT was only increased in long-haul travellers if one or more additional risk factors were present, with an odds ratio of 3.0 (CI 1.1-8.2). Such individuals may benefit from prophylactic measures to minimize risk...
  34. pmc Fatal pulmonary embolism in hospitalised patients: a necropsy review
    R Alikhan
    Department of Medicine, Royal United Hospital, Combe Park, Bath BA1 3NG, UK
    J Clin Pathol 57:1254-7. 2004
    ..To carry out a retrospective review of all postmortem reports during the period 1991 to 2000 at King's College Hospital, London, as an extension of a previous analysis performed for the period 1965 to 1990...
  35. doi request reprint Venous thromboembolism risk and prophylaxis in the acute care hospital setting (ENDORSE survey): findings in surgical patients
    Ajay K Kakkar
    Barts and the London School of Medicine and Dentistry, London, United Kingdom
    Ann Surg 251:330-8. 2010
    ..To evaluate venous thromboembolism (VTE) risk in patients who underwent a major operation, including the use of, and factors influencing, American College of Chest Physicians-recommended types of VTE prophylaxis...
  36. doi request reprint Venous thromboembolism prophylaxis for the medical patient: where do we stand?
    Yshai Yavin
    Vascular Medicine, Department of Vascular Surgery, King s College Hospital, London, UK
    Semin Respir Crit Care Med 29:75-82. 2008
    ..There is no evidence for the use of aspirin, warfarin, or mechanical methods. We recommend either low molecular weight heparin or fondaparinux as safe and effective agents in the thromboprophylaxis of medical patients...
  37. ncbi request reprint Risk factors for venous thromboembolism in orthopedic surgery
    Htwe M Zaw
    Vascular Diseases Research Group, Academic Department of Surgery, Guy s King s and St Thomas School of Medicine, London, UK
    Isr Med Assoc J 4:1040-2. 2002
  38. ncbi request reprint Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial
    Nils Kucher
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Arch Intern Med 165:341-5. 2005
    ..We were concerned that a fixed rather than a weight-based dosing regimen of dalteparin sodium to prevent venous thromboembolism (VTE) might result in decreased efficacy in obese patients and decreased safety in elderly patients...
  39. ncbi request reprint Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer
    David Bergqvist
    Academic Hospital, Uppsala, Sweden
    N Engl J Med 346:975-80. 2002
    ..Abdominal surgery for cancer carries a high risk of venous thromboembolism, but the optimal duration of postoperative thromboprophylaxis is unknown...
  40. ncbi request reprint Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United
    Marc F Botteman
    International Health Economics, HERQuLES, Abt Associates Clinical Trials, Bethesda, Maryland 20814, USA
    Clin Ther 24:1960-86; discussion 1938. 2002
    ..The long-term clinical course after DVT can be further complicated by excess mortality, recurrent venous thromboembolism (VTE), and the post-thrombotic syndrome (PTS), which may produce sizable long-term economic burdens...
  41. ncbi request reprint Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States
    Joseph A Caprini
    Evanston Northwestern Healthcare, Evanston, IL, USA
    Value Health 6:59-74. 2003
    ..Estimates of the cost of long-term complications of a primary deep vein thrombosis (DVT), including the post-thrombotic syndrome (PTS) and recurrent venous thromboembolism (VTE), may be relevant for resource allocation decisions...
  42. ncbi request reprint Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement
    Bengt I Eriksson
    Orthopaedics Department, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    Thromb Haemost 89:288-96. 2003
    ..0%) and 306/1122 (27.3%) patients in the ximelagatran and enoxaparin group, respectively, a difference in risk of 3.7% in favour of enoxaparin (p = 0.053). Bleeding was comparable between the two groups...
  43. ncbi request reprint A safety analysis of thromboprophylaxis in acute medical illness
    Raza Alikhan
    Thromb Haemost 89:590-1. 2003
  44. ncbi request reprint Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients
    Paul T Vaitkus
    Cardiology Division, College of Medicine, University of Illinois at Chicago, 840 S Wood St, Chicago, Illinois 60612, USA
    Thromb Haemost 93:76-9. 2005
    ..In conclusion, the high mortality rate in patients with asymptomatic proximal DVT underscores its clinical relevance and supports targeting of asymptomatic proximal DVT as an appropriate endpoint in clinical trials of thromboprophylaxis...
  45. ncbi request reprint Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism
    Frederick A Anderson
    Center for Outcomes Research, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA
    Am J Hematol 82:777-82. 2007
    ..Given the existence of internationally-accepted evidence-based guidelines for prevention of VTE, research is required to establish if this patient population is receiving recommended VTE prophylaxis...
  46. ncbi request reprint Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients
    Alain Leizorovicz
    Unite de Pharmacologie Clinique, Universite Claude Bernard Lyon I, Lyon, France
    Circulation 110:874-9. 2004
    ....
  47. ncbi request reprint Correlation of plasma coagulation parameters with thromboprophylaxis, patient characteristics, and outcome in the MEDENOX study
    Louis Desjardins
    Service hématologie, CHU Laval, Ste Foy, Quebec, Canada
    Arch Pathol Lab Med 128:519-26. 2004
    ..Plasma anti-Xa and anti-IIa activities correlate with the dose of low-molecular-weight heparin, and D-dimer and thrombin-antithrombin complexes are markers of procoagulant activity...